Streetbeat News

Products Services

EVAX

Evaxion Biotech A/S (NASDAQ:EVAX) will present one-year clinical efficacy data from its Phase 2 study on its lead cancer vaccine candidate, EVX-01, at the ESMO Congress 2024. The vaccine is being tested in patients with advanced melanoma.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:06 pm

MSFT

PLTR

Microsoft and Palantir have announced an expanded partnership to deploy AI tools for U.S. government agencies. The collaboration will integrate Microsoft's large language models via Azure OpenAI Service with Palantir's AI platforms in Microsoft's government cloud environments. This partnership aims to enhance AI and analytics capabilities for the U.S. Defense and Intelligence Community.

Portfolio Pulse from Benzinga Neuro

August 08, 2024 | 12:05 pm

BA

Boeing CEO Kelly Ortberg announced plans to base himself in Seattle to be closer to the company's commercial airplane programs.

Portfolio Pulse from charles@benzinga.com

August 08, 2024 | 12:04 pm

NEXN

Nexxen has announced a partnership with Vevo to expand Vevo's programmatic advertising reach through Nexxen's supply-side platform, Nexxen SSP. This partnership will allow a wider variety of advertisers to access Vevo's premium inventory, especially across connected TV (CTV).

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:02 pm

RNAC

Cartesian Therapeutics has $88.9M in cash and net proceeds from $130M PIPE financing to support the development of Descartes-08 for Myasthenia Gravis. An end-of-phase 2 meeting with the FDA is expected by year-end.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:56 am

QTTB

Q32 Bio has $107.6M in cash, cash equivalents, and short-term investments as of June 30, 2024. This financial position is expected to support the company through four Phase 2 clinical milestones and into mid-2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:53 am

GNSS

Genasys shares are trading higher following the announcement of a definitive agreement with the Puerto Rico Electric Power Authority to implement its Emergency Warning System across 37 dams.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:52 am

CTXR

The FDA has approved Citius Pharmaceuticals' Lymphir (Denileukin Diftitox-cxdl) for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. This marks the first indication for Lymphir and the first FDA-approved product for Citius Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:50 am

NNVC

NanoViricides has provided an update on its clinical program and strategy in a letter to shareholders. The company highlighted NV-387, an antiviral drug, which it claims could be as revolutionary as antibiotics.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:46 am

DOGEUSD

Dogecoin (DOGE) is attracting bullish predictions from traders who believe it has 'fairly bottomed' and anticipate potential growth, especially with the expected introduction of X payments. Despite a drop in large transaction volumes, daily active addresses have increased. The Dogecoin Foundation highlights the importance of the Cardinals protocol for innovation in the ecosystem.

Portfolio Pulse from Khyathi Dalal

August 08, 2024 | 11:40 am